According to a new report published by UnivDatos, the EGFR-NSCLC Market was valued at USD 6,762.75 million in 2022 & is expected to grow at a CAGR of 6.7% from 2022-2030. The analysis has been segmented into Drug Type (Erlotinib, Afatinib, Gefitinib, Osimertinib, and Dacomitinib); Distribution Channel  (Offline and Online); Region/Country.

The EGFR-NSCLC Market report has been aggregated by collecting informative data on various dynamics such as market drivers, restraints, and opportunities. This innovative report makes use of several analyses to get a closer outlook on the EGFR-NSCLC Market. The EGFR-NSCLC Market report offers a detailed analysis of the latest industry developments and trending factors in the market that are influencing market growth. Furthermore, this statistical market research repository examines and estimates the EGFR-NSCLC Market at the global and regional levels.

Key Market Dynamics

The rising prevalence of non-small cell lung cancer (NSCLC) is a key driver for the growth of the EGFR-NSCLC market. NSCLC accounts for most lung cancer cases, and within NSCLC, the subset of patients with epidermal growth factor receptor (EGFR) mutations represents a significant proportion. According to global cancer statistics, lung cancer is one of the most diagnosed cancers, with NSCLC comprising around 80-85% of all cases. Among NSCLC patients, EGFR mutations are detected in approximately 10-15% of cases in non-Asian populations and in a higher percentage, around 30-40%, among Asian populations. As awareness and early detection efforts increase, more patients are being diagnosed with EGFR-mutated NSCLC, driving the demand for targeted therapies tailored to this specific mutation. This rising prevalence underscores the urgent need for effective treatment options and is a central factor fueling research, development, and investments in the EGFR-NSCLC market.

Access sample report (including graphs, charts, and figures): https://univdatos.com/reports/egfr-nsclc-market?popup=report-enquiry

The global EGFR-NSCLC Market report is studied thoroughly with several aspects that would help stakeholders in making their decisions more curated.

·       By drug type, the market is segmented into Erlotinib, Afatinib, Gefitinib, Osimertinib, and Dacomitinib. Among these, Osimertinib category captured the majority share of the EGFR-NSCLC Market in 2022.

·       On the basis of distribution channel, the market is bifurcated into Online and Offline. The Offline category held a major share of the EGFR-NSCLC Market in 2022 and are expected to grow at a substantial CAGR during the forecasted period.

Have a Look at the Chapters

EGFR-NSCLC Market Geographical Segmentation Includes:

·       North America (U.S., Canada, and the Rest of North America)

·       Europe (Germany, UK, France, Italy, Spain, Rest of Europe)

·       Asia-Pacific (China, India, Japan, and Rest of Asia-Pacific)

·       Rest of the World

North America region is expected to dominate the EGFR-NSCLC market during the forecast period. The region's robust healthcare infrastructure, coupled with high awareness levels among patients and healthcare providers, has spurred the demand for advanced treatment options. The prevalence of non-small cell lung cancer cases with EGFR mutations has prompted pharmaceutical companies to focus on R&D, resulting in the introduction of innovative targeted therapies. For Instance, as per the American Cancer Society, about 238,340 new cases of lung cancer (117,550 in men and 120,790 in women) were diagnosed in 2023 till now.

Competitive Landscape

The degree of competition among prominent global companies has been elaborated by analyzing several leading key players operating worldwide. The specialist team of research analysts sheds light on various traits such as global market competition, market share, most recent industry advancements, innovative product launches, partnerships, mergers, or acquisitions by leading companies in the EGFR-NSCLC Market. The major players have been analyzed by using research methodologies such as Porter’s Five Forces Analysis for getting insight views on global competition.

Recent Developments:

·       on April 4, 2022, Janssen Pharmaceutical announced that Health Canada has issued a Notice of Compliance with Conditions (NOC/c) approving RYBREVANT (amivantamab), a fully human, bispecific antibody, for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR Exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.

·       In January 2023, announced that EXKIVITY (mobocertinib) has been approved by the National Medical Products Administration (NMPA) of China for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy.

Click here to view the Report Description & TOC: https://univdatos.com/reports/egfr-nsclc-market

Key questions resolved through this analytical market research report include:

• What are the latest trends, new patterns, and technological advancements in the EGFR-NSCLC Market?

• Which factors are influencing the EGFR-NSCLC Market over the forecast period?

• What are the global challenges, threats, and risks in the EGFR-NSCLC Market?

• Which factors are propelling and restraining the EGFR-NSCLC Market?

• What are the demanding global regions of the EGFR-NSCLC Market?

• What will be the global market size in the upcoming years?

• What are the crucial market acquisition strategies and policies applied by global companies?

• What are the descriptive profiles of key companies along with their SWOT analysis?

We understand the requirement of different businesses, regions, and countries, we offer customized reports as per your requirements of business nature and geography. Please let us know If you have any custom needs.

Contact Us:

UnivDatos

Contact Number - +1 978 733 0253

Email - contact@univdatos.com 

Website - www.univdatos.com

Linkedin- https://www.linkedin.com/company/univ-datos-market-insight/mycompany/